Volume 19, Issue 3, Pages (March 2017)

Slides:

Advertisements

Similar presentations

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Advertisements

EGFR Mutations in Lung Adenocarcinomas

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading.

Figure 1 Overview of the IMPACT Analysis Pipeline

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Comparison of Clinical Targeted Next-Generation Sequence Data from Formalin-Fixed and Fresh-Frozen Tissue Specimens David H. Spencer, Jennifer K. Sehn,

Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach Volker Endris, Roland Penzel,

Unità Clinica di Diagnostica Istopatologica e Molecolare

DNA Extraction of Lung Cancer Samples for Advanced Diagnostic Testing

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology Marlous Hoogstraat, John W.J. Hinrichs, Nicolle.

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors Rajyalakshmi.

Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data Catherine Grasso, Timothy Butler, Katherine Rhodes, Michael.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer Maruja E. Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui.

TERT and AURKA Gene Copy Number Gains Enhance the Detection of Acral Lentiginous Melanomas by Fluorescence in Situ Hybridization Alba Diaz, Joan Anton.

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin- Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens Andrew.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Multiplex Preamplification of Serum DNA to Facilitate Reliable Detection of Extremely Rare Cancer Mutations in Circulating DNA by Digital PCR Jennifer.

A Multiplex SNaPshot Assay as a Rapid Method for Detecting KRAS and BRAF Mutations in Advanced Colorectal Cancers Sandrine Magnin, Erika Viel, Alice.

KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers Katharina Balschun, Jochen Haag, Ann-Kathrin.

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center Anthony N. Sireci, Vimla S. Aggarwal, Andrew T.

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis

Simultaneous Detection of Clinically Relevant Mutations and Amplifications for Routine Cancer Pathology Marlous Hoogstraat, John W.J. Hinrichs, Nicolle.

European Urology Oncology

Christopher R. Cabanski, Vincent Magrini, Malachi Griffith, Obi L

Donavan T. Cheng, Talia N. Mitchell, Ahmet Zehir, Ronak H

CRISPR/Cas9 Technology–Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing Rongxue Peng, Rui Zhang,

A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses Zachary S. Boyd, Rajiv Raja,

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative.

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR Marie.

Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer Maruja E. Lira, Tae Min Kim, Donghui Huang, Shibing Deng,

Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and.

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients Clotilde Descarpentries, PharmD, Frédéric Leprêtre, PhD, Fabienne.

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma Jin Sung Jang, Xiaoke Wang,

Markus Rechsteiner, Adriana von Teichman, Jan H

Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma

Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma Cynthia Spittle, M. Renee Ward, Katherine.

Utility of NIST Whole-Genome Reference Materials for the Technical Validation of a Multigene Next-Generation Sequencing Test Bennett O.V. Shum, Ilya.

Volume 130, Issue 3, Pages (September 2013)

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Personalized Medicine: Patient-Predictive Panel Power

Figure 1. Plasma next-generation sequencing (NGS) assay workflow, comparison of variant allelic fraction with ... Figure 1. Plasma next-generation sequencing.

EGFR Mutations in Lung Adenocarcinomas

A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non–Small-Cell Lung Cancer (NSCLC) Bronchoscopy.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Volume 9, Issue 4, Pages (November 2014)

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer Zengliu Su, Dora Dias-Santagata,

Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes Rajesh R. Singh, Keyur P. Patel, Mark J.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas Qiulu Pan, William Pao, Marc.

Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid.

Dara S. Ross, Ahmet Zehir, Donavan T

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers Ryoichi Onozato, MD,

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania Erin L. Crowgey,

Presentation transcript:

Volume 19, Issue 3, Pages 196-206 (March 2017) Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors Aino Paasinen-Sohns, Viktor H. Koelzer, Angela Frank, Julian Schafroth, Aline Gisler, Melanie Sachs, Anne Graber, Sacha I. Rothschild, Andreas Wicki, Gieri Cathomas, Kirsten D. Mertz Neoplasia Volume 19, Issue 3, Pages 196-206 (March 2017) DOI: 10.1016/j.neo.2017.01.003 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Molecular profiling with the OFA, a targeted multibiomarker NGS assay. (A) The OFA is a targeted NGS panel that includes 52 solid tumor genes associated with current oncology drugs and published evidence. It enables sequencing of 35 hotspot genes, 19 genes associated with copy number gain, and 23 fusion genes, all in a single workflow using the Ion PGM system. Genes printed in bold were detected in cases of the two cohorts studied here. (B) Workflow and turnaround time for molecular profiling of clinical FFPE samples using targeted NGS with the OFA. (C) Design of this study. The OFA was tested and validated on two different cohorts. Cohort I (left) consisted of 59 routine FFPE samples from 51 patients with various solid tumors that were routinely submitted to the molecular pathology service. Half of these samples were randomly selected for orthogonal validation by alternative tests. In addition, validation was performed by comparing the OFA results with expected mutation frequencies from the literature. Cohort II (right) was an archival cohort of 39 FFPE melanoma samples from 39 patients. Mutation frequencies were retrieved from the literature, and the samples of cohort II were analyzed by the OFA retrospectively. The OFA results of the melanomas in cohort II were consistent with the data that can be expected from large published cohorts of cutaneous melanomas. Neoplasia 2017 19, 196-206DOI: (10.1016/j.neo.2017.01.003) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Validation of gene fusions and SCNVs detected in routine FFPE samples. (A) EML4-ALK intrachromosomal fusion found in sample no. 32 (NSCLC, adenocarcinoma, H&E left). Confirmation of ALK overexpression due to this EML4-ALK gene fusion by IHC (right). (B) CD74-ROS1 fusion found in sample no. 25 (NSCLC, adenocarcinoma, H&E left). Confirmation of ROS1 overexpression due to this gene fusion between CD74 (Exon 6) and ROS1 (Exon 34) by IHC (right). (C) Intragenic MET fusion (Exon 13-Exon 15; MET “exon 14 skipping”) found in sample no. 29 (lung metastasis of CRC, H&E left). Confirmation of membranous MET overexpression due to this MET exon 14 mutation by IHC (right). (D) MYC amplification found in sample no. 27 (CRC, H&E left). The gene region 8q24.21 on chromosome 8 had a copy number of 25. Confirmation of MYC amplification by IHC (right). Neoplasia 2017 19, 196-206DOI: (10.1016/j.neo.2017.01.003) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Genomic aberrations in different tumor types. (A) Actionable variants in 20 CRC patients (n=number of patients) (left). Distribution of KRAS mutations that were detected in 11 (55%) CRC patients (right). (B) Actionable variants detected in 19 NSCLC patients (left). Distribution of KRAS mutations that were detected in six (31.6%) NSCLC patients (right). One NSCLC patient harbored two different KRAS mutations (p. G12C and p. A59G). (C) Actionable variants detected in 39 melanoma patients (left). Distribution of BRAF (right, top panel) and NRAS (right, bottom panel) mutations identified in 14 (35.9%) melanomas. Neoplasia 2017 19, 196-206DOI: (10.1016/j.neo.2017.01.003) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Detection and validation of an ALK translocation in one archival melanoma. (A) Relatively symmetrical, exophytic, predominantly intradermal melanocytic tumor with focal epidermal hyperplasia from the right earlobe of a 30-year-old man. (B) Plexiform growth pattern and intersecting fascicles of fusiform melanocytes. Proliferation of spindle and epithelioid melanocytes. (C) The neoplastic melanocytes are positive for ALK in IHC, with strong staining of the cytoplasm. The ALK expression confirms the presence of a TPM3-ALK fusion in this melanoma which was retrospectively reclassified as a melanoma with spitzoid features. Neoplasia 2017 19, 196-206DOI: (10.1016/j.neo.2017.01.003) Copyright © 2017 The Authors Terms and Conditions